Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer

Cancer Letters

Volumn 346, Issue 1, 2014, Pages 24-33

  Lim, S H ^a,b,c,d   Becker, T M ^a,c,d   Chua, W ^b,d   Caixeiro, N J ^a,d,e   Ng, W L ^b,d   Kienzle, N ^a,c,d   Tognela, A ^a,b,d,e   Lumba, S ^a,b,c,d   Rasko, J E J ^f,g   De Souza, P ^a,b,c,d,e   Spring, K J ^a,d,e  

^a INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d South West Sydney Translational Cancer Research Unit ^*  (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Circulating free DNA; Circulating free RNA; Circulating tumour cells; Colorectal cancer; Personalised cancer therapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CIRCULATING FREE DNA; CIRCULATING FREE RNA; CYTOKERATIN 20; EPITHELIAL CELL ADHESION MOLECULE; NUCLEIC ACID; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; CANCER GROWTH; CANCER STAGING; CELL COUNT; CELL PROLIFERATION; CIRCULATING TUMOR CELL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LYMPH NODE METASTASIS; METASTATIC COLORECTAL CANCER; MINIMALLY INVASIVE PROCEDURE; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; SHORT SURVEY; TUMOR BIOPSY;

CIRCULATING FREE DNA; CIRCULATING FREE RNA; CIRCULATING TUMOUR CELLS; COLORECTAL CANCER; PERSONALISED CANCER THERAPY;

COLORECTAL NEOPLASMS; DNA; HUMANS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84896740331     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.12.019     Document Type: Review

References (70)

1. Miron N., Susman S., Balacescu O., Buiga R., Berindan-Neagoe I., Cristea V., et al. Novel cellular and molecular approaches to stratification and treatment of colorectal cancer. J. Gastrointest. Liver Dis.: JGLD 2012, 21(4):413-421. Epub 2012/12/21.
2. De Mattos-Arruda L., Olmos D., Tabernero J. Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol. 2011, 7(12):1385-1397. Epub 2011/11/25.
3. Allen J.E., El-Deiry W.S. Circulating tumor cells and colorectal cancer. Curr. Colorectal Cancer Rep. 2010, 6(4):212-220. Epub 2010/10/05.
4. Alix-Panabieres C., Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin. Chem. 2013, 59(1):110-118. Epub 2012/09/28.
5. Liberko M., Kolostova K., Bobek V. Essentials of circulating tumor cells for clinical research and practice. Crit. Rev. Oncol./Hematol. 2013, Epub 2013/07/09.
6. Kin C., Kidess E., Poultsides G.A., Visser B.C., Jeffrey S.S. Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev. Mol. Diagn. 2013, 13(6):581-599. Epub 2013/07/31.
7. Ashworth T.R. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 1869, 14:146-149.
8. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11(6):426-437. Epub 2011/05/13.
9. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Nat. Acad. Sci. USA 2005, 102(45):16368-16373. Epub 2005/11/01.
10. Heitzer E., Auer M., Gasch C., Pichler M., Ulz P., Hoffmann E.M., et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013, 73(10):2965-2975. Epub 2013/03/09.
11. Becker T.M., Caixeiro N.J., Lim S.H., Tognela A., Kienzle N., Scott K.F., et al. New frontiers in circulating tumor cell analysis - a reference guide for biomolecular profiling towards translational clinical use. Int. J. Cancer J. Int. Cancer 2013, Epub 2013/10/15.
12. Groot Koerkamp B., Rahbari N.N., Buchler M.W., Koch M., Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann. Surg. Oncol. 2013, 20(7):2156-2165. Epub 2013/03/05.
13. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2008, 26(19):3213-3221. Epub 2008/07/02.
14. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2009, 20(7):1223-1229.
15. Matsusaka S., Suenaga M., Mishima Y., Kuniyoshi R., Takagi K., Terui Y., et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2011, 102(6):1188-1192. Epub 2011/03/16.
16. Sorbye H., Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2003, 21(23):4466-4467. Epub 2003/12/04.
17. Sastre J., Maestro M.L., Gomez-Espana A., Rivera F., Valladares M., Massuti B., et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish cooperative group for the treatment of digestive tumors study. Oncologist 2012, 17(7):947-955. Epub 2012/05/31.
18. Kawahara H., Watanabe K., Toyama Y., Yanagisawa S., Kobayashi S., Yanaga K. Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression. Hepatogastroenterology 2012, 59(119). Epub 2012/02/14.
19. Gazzaniga P., Gradilone A., Petracca A., Nicolazzo C., Raimondi C., Iacovelli R., et al. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. J. Cell Mol. Med. 2010, 14(8):2073-2077. Epub 2010/07/06.
20. Yang C.Y., Lin C.H., Jiang J.K. Early relapse in a rectal cancer patient: possible implication of circulating cancer stem cell. J. Surg. Oncol. 2010, 102(2):196-197. Epub 2010/07/22.
21. Pilati P., Mocellin S., Bertazza L., Galdi F., Briarava M., Mammano E., et al. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann. Surg. Oncol. 2012, 19(2):402-408. Epub 2011/11/11.
22. Faltas B., Zeidan A., Peters K., Das A., Joudeh J., Navaraj A., et al. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2011, 29(21):2946-2947. Epub 2011/06/22.
23. LaBarge M.A., Bissell M.J. Is CD133 a marker of metastatic colon cancer stem cells?. J. Clin. Invest. 2008, 118(6):2021-2024.
24. Sastre J., Maestro M.L., Puente J., Veganzones S., Alfonso R., Rafael S., et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2008, 19(5):935-938. Epub 2008/01/24.
25. Benson A.B., Schrag D., Somerfield M.R., Cohen A.M., Figueredo A.T., Flynn P.J., et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2004, 22(16):3408-3419. Epub 2004/06/17.
26. Maestro L.M., Sastre J., Rafael S.B., Veganzones S.B., Vidaurreta M., Martin M., et al. Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res. 2009, 29(11):4839-4843. Epub 2009/12/25.
27. Neki K., Kawahara H., Watanabe K., Toyama Y., Akiba T., Yanaga K. Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer. Anticancer Res. 2013, 33(4):1769-1772. Epub 2013/04/09.
28. Aggarwal C., Meropol N.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2013, 24(2):420-428.
29. Tol J., Koopman M., Miller M.C., Tibbe A., Cats A., Creemers G.J., et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2010, 21(5):1006-1012. Epub 2009/10/29.
30. Thorsteinsson M., Jess P. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer-a review. Eur. J. Surg. Oncol.: J. Eur. Soc. Surg. Oncol. Brit. Assoc. Surg. Oncol. 2011, 37(6):459-465. Epub 2011/02/18.
31. Thorsteinsson M., Soletormos G., Jess P. Low number of detectable circulating tumor cells in non-metastatic colon cancer. Anticancer Res. 2011, 31(2):613-617. Epub 2011/03/08.
32. Hiraiwa K., Takeuchi H., Hasegawa H., Saikawa Y., Suda K., Ando T., et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann. Surg. Oncol. 2008, 15(11):3092-3100. Epub 2008/09/04.
33. Wind J., Tuynman J.B., Tibbe A.G., Swennenhuis J.F., Richel D.J., Van Berge Henegouwen M.I., et al. Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. Eur. J. Surg. Oncol.: J. Eur. Soc. Surg. Oncol. Brit. Assoc. Surg. Oncol. 2009, 35(9):942-950. Epub 2009/01/21.
34. Lu C.Y., Uen Y.H., Tsai H.L., Chuang S.C., Hou M.F., Wu D.C., et al. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. Br. J. Cancer 2011, 104(7):1178-1184. Epub 2011/02/24.
35. Lu C.Y., Tsai H.L., Uen Y.H., Hu H.M., Chen C.W., Cheng T.L., et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br. J. Cancer 2013, 108(4):791-797. Epub 2013/02/21.
36. Iinuma H., Watanabe T., Mimori K., Adachi M., Hayashi N., Tamura J., et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2011, 29(12):1547-1555. Epub 2011/03/23.
37. Koyanagi K., Bilchik A.J., Saha S., Turner R.R., Wiese D., McCarter M., et al. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2008, 14(22):7391-7396. Epub 2008/11/18.
38. Kienle P., Koch M., Autschbach F., Benner A., Treiber M., Wannenmacher M., et al. Decreased detection rate of disseminated tumor cells of rectal cancer patients after preoperative chemoradiation: a first step towards a molecular surrogate marker for neoadjuvant treatment in colorectal cancer. Ann. Surg. 2003, 238(3):324-330. discussion 30-1. Epub 2003/09/23.
39. Lloyd J.M., McIver C.M., Stephenson S.A., Hewett P.J., Rieger N., Hardingham J.E. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2006, 12(2):417-423. Epub 2006/01/24.
40. Wang J.Y., Lin S.R., Wu D.C., Lu C.Y., Yu F.J., Hsieh J.S., et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2007, 13(8):2406-2413. Epub 2007/04/05.
41. Parkinson D.R., Dracopoli N., Petty B.G., Compton C., Cristofanilli M., Deisseroth A., et al. Considerations in the development of circulating tumor cell technology for clinical use. J. Translational Med. 2012, 10:138. Epub 2012/07/04.
42. Lalmahomed Z.S., Kraan J., Gratama J.W., Mostert B., Sleijfer S., Verhoef C. Circulating tumor cells and sample size: the more, the better. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2010, 28(17):e288-289. author reply e90. Epub 2010/05/05.
43. Baccelli I., Schneeweiss A., Riethdorf S., Stenzinger A., Schillert A., Vogel V., et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 2013, 31(6):539-544. Epub 2013/04/24.
44. Muller V., Stahmann N., Riethdorf S., Rau T., Zabel T., Goetz A., et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2005, 11(10):3678-3685. Epub 2005/05/18.
45. Rossi E., Basso U., Celadin R., Zilio F., Pucciarelli S., Aieta M., et al. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16(21):5233-5243. Epub 2010/10/28.
46. Rossi E., Fassan M., Aieta M., Zilio F., Celadin R., Borin M., et al. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br. J. Cancer 2012, 107(8):1286-1294. Epub 2012/09/08.
47. Heitzer E., Auer M., Hoffmann E.M., Pichler M., Gasch C., Ulz P., et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int. J. Cancer J. Int. Cancer 2013, 133(2):346-356. Epub 2013/01/16.
48. Meng S., Tripathy D., Frenkel E.P., Shete S., Naftalis E.Z., Huth J.F., et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2004, 10(24):8152-8162.
49. Uhr J.W., Pantel K. Controversies in clinical cancer dormancy. Proc. Nat. Acad. Sci. USA 2011, 108(30):12396-12400. Epub 2011/07/13.
50. Bidard F.C., Pierga J.Y., Soria J.C., Thiery J.P. Translating metastasis-related biomarkers to the clinic-progress and pitfalls. Nat. Rev. Clin. Oncol. 2013, 10(3):169-179. Epub 2013/02/06.
51. Konstantopoulos K., Thomas S.N. Cancer cells in transit: the vascular interactions of tumor cells. Annu. Rev. Biomed. Eng. 2009, 11:177-202. Epub 2009/05/06.
52. Levesque J.P., Winkler I.G., Rasko J.E. Nichotherapy for stem cells: there goes the neighborhood. BioEssays: News Rev. Mol., Cell. Develop Biol. 2013, 35(3):183-190. Epub 2012/11/07.
53. Zhe X., Cher M.L., Bonfil R.D. Circulating tumor cells: finding the needle in the haystack. Am. J. Cancer Res. 2011, 1(6):740-751. Epub 2011/10/22.
54. Wicha M.S., Hayes D.F. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2011, 29(12):1508-1511. Epub 2011/03/23.
55. Yokobori T., Iinuma H., Shimamura T., Imoto S., Sugimachi K., Ishii H., et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013, 73(7):2059-2069. Epub 2013/02/05.
56. Winter M.J., Nagelkerken B., Mertens A.E., Rees-Bakker H.A., Briaire-de Bruijn I.H., Litvinov S.V. Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp. Cell Res. 2003, 285(1):50-58. Epub 2003/04/12.
57. Barbazan J., Alonso-Alconada L., Muinelo-Romay L., Vieito M., Abalo A., Alonso-Nocelo M., et al. Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PLoS One 2012, 7(7):e40476. Epub 2012/07/20.
58. Balic M., Williams A., Dandachi N., Cote R.J. Micrometastasis: detection methods and clinical importance. Cancer Biomarkers: Sect. A Dis. Markers 2010, 9(1-6):397-419. Epub 2011/11/25.
59. Gasch C., Bauernhofer T., Pichler M., Langer-Freitag S., Reeh M., Seifert A.M., et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 2013, 59(1):252-260.
60. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Eng. J. Med. 2008, 359(17):1757-1765.
61. Claret L., Gupta M., Han K., Joshi A., Sarapa N., He J., et al. Evaluation of tumor-size response metrics to predict overall survival in Western and chinese patients with first-line metastatic colorectal cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2013, 31(17):2110-2114. Epub 2013/05/08.
62. Maitland M.L., Schwartz L.H., Ratain M.J. Time to tumor growth: a model end point and new metric system for oncology clinical trials. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2013, 31(17):2070-2072. Epub 2013/05/08.
63. Budinska E., Popovici V., Tejpar S., D'Ario G., Lapique N., Sikora K.O., et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 2013, 231(1):63-76. Epub 2013/07/10.
64. Lecomte T., Berger A., Zinzindohoue F., Micard S., Landi B., Blons H., et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer J. Int. Cancer 2002, 100(5):542-548. Epub 2002/07/19.
65. Wang J.Y., Hsieh J.S., Chang M.Y., Huang T.J., Chen F.M., Cheng T.L., et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J. Surg. 2004, 28(7):721-726. Epub 2004/06/09.
66. Da Silva Filho B.F., Gurgel A.P., Neto M.A., De Azevedo D.A., De Freitas A.C., Silva Neto Jda C., et al. Circulating cell-free DNA in serum as a biomarker of colorectal cancer. J. Clin. Pathol. 2013, 66(9):775-778. Epub 2013/07/09.
67. Lee H.S., Hwang S.M., Kim T.S., Kim D.W., Park do J., Kang S.B., et al. Circulating methylated septin 9 nucleic acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. Translational Oncol. 2013, 6(3):290-296. Epub 2013/06/05.
68. Grutzmann R., Molnar B., Pilarsky C., Habermann J.K., Schlag P.M., Saeger H.D., et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008, 3(11):e3759. Epub 2008/11/20.
69. Philipp A.B., Stieber P., Nagel D., Neumann J., Spelsberg F., Jung A., et al. Prognostic role of methylated free circulating DNA in colorectal cancer. Int. J. Cancer J. Int. Cancer 2012, 131(10):2308-2319. Epub 2012/03/01.
70. Lefebure B., Charbonnier F., Di Fiore F., Tuech J.J., Le Pessot F., Michot F., et al. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. Ann. Surg. 2010, 251(2):275-280. Epub 2009/12/17.